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ABSTRACT   
Objective  To determine factors associated with symptom detected breast cancers in a population 
offered screening.  
Methods  We interviewed 1,459 Australian women aged 40–69, 946 with symptom detected and 
513 with mammogram detected invasive breast cancers ≥1.1 cm in diameter, about their 
personal, mammogram and breast histories before diagnosis and reviewed medical records for 
tumour characteristics and mammogram dates, calculating ORs and 95% confidence intervals 
(CIs) for symptom- vs mammogram-detected cancers in logistic regression models. 
Results  Lack of regular mammograms (<2 mammograms in the 4.5 years before diagnosis) was 
the strongest correlate of symptom detected breast cancer (OR=3.04 for irregular or no 
mammograms). In women who had regular mammograms (≥2 mammograms in the 4.5 years 
before diagnosis), the independent correlates of symptom detected cancers were low BMI (OR 
<25kg/m2 vs ≥30kg/m2=2.18, 95% CI 1.23-3.84; p=0.008), increased breast density (available in 
498 women) (OR highest quarter vs lowest =3.50, 95% CI 1.76-6.97; ptrend=0.004), high grade 
cancer and a larger cancer (each p<0.01). In women who did not have regular mammograms, the 
independent correlates were age <50 years, a first cancer and a ≥2cm cancer. Smoking appeared 
to modify the association of symptom detected cancer with low BMI (higher ORs for low BMI 
in current smokers) and estrogen receptor (ER) status (higher ORs for low BMI in ER− cancers).  
Conclusion  Women with low BMI may benefit from a tailored approach to breast cancer 
detection, particularly if they smoke.  
INTRODUCTION  
Most breast cancers are detected following the appearance of symptoms or signs [1,2] 
despite the ability of organised mammography screening to detect breast cancers when they are 
small [3]. Organised screening programs target women at highest risk for breast cancer and, 
typically, more than half the women in targeted age groups accept screening. In 2002-2003, 
56.1% of Australian women aged 50-69 years participated in an organised screening program, 
BreastScreen Australia [4]. However, many breast cancers diagnosed in women who are 
screened regularly are not screen detected [5,6]. We estimated from BreastScreen Australia data 
for 1997 [7] and 2000-2004 data from the New South Wales and Queensland Cancer Registries 
(personal communication) that symptom detected breast cancers made up some 46-50% of all 
breast cancers of any size in Australian women 50-69 years in 2002-2003.  
Symptom detected breast cancers are under-researched despite their common occurrence in 
populations offered mammographic screening. Interval cancers in screened women are usually 
characterised as larger and having less favourable pathology characteristics than screen-detected 
breast cancers [8], but little is otherwise known about symptom detected breast cancers. We 
sought, therefore, to identify characteristics of women, their cancers and their health services 
that distinguished between symptom detected breast cancers and mammogram detected cancers 
in a population offered screening [3]. Our study includes a population-based sample of women 
who were diagnosed with breast cancer in 2002-2003 in Australia where biennial screening 
mammography is offered free of charge to women 50-69 years of age.  
MATERIALS AND METHODS 
Study population 
Eligible women were 20-69 years of age and newly notified to cancer registries in three 
Australian states (New South Wales, Victoria and Queensland) with a first primary invasive 
breast cancer 1.1cm or larger diagnosed between March 2002 and December 2003. The study 
was designed principally to identify factors other than lack of mammographic screening that 
might contribute to diagnosis with a large breast cancer [9]. It excluded tumors <1.1cm, which 
we estimated to be about 20% of breast cancers diagnosed in Australia and 60% of breast 
cancers detected in women 50-69 years by the national, publicly-funded screening program, 
BreastScreen Australia, in 1997 [7]. We have already reported on correlates of diagnosis with a 
larger breast cancer, by comparing breast cancers ≥2cm with those 1.1-1.9cm in diameter [9].  
BreastScreen Australia offers biennial mammograms as the sole screening modality to 
women aged 50-69; women aged 40-49 or 70+ years are also able to attend. Private radiology 
practices also provide screening mammograms, the cost of which is usually reimbursed by the 
national health insurance scheme (Medicare). This analysis was limited to 1,459 women aged 
40-69 years of age.  
Women were recruited by state cancer registries asking doctors for their agreement to us 
inviting women to participate. Women participated by completing a self-administered 
questionnaire and a computer-assisted telephone interview (CATI), and by giving written 
consent for the study to obtain basic information and pathology characteristics of their breast 
cancers from cancer registry records and mammogram dates from medical records. The study 
was approved by the cancer registries’ ethics committees and those of the investigators’ host 
institutions. Most participating women (90%) were interviewed within 12 months of diagnosis; 
on average, interviews were completed 7.5 months after diagnosis (range 2.1 to 20.4 months). 
The study procedures have been described in detail elsewhere [9]. 
Data collection 
Breast cancer size and diagnosis date were extracted from cancer registry records and 
verified in pathology reports. Reproductive history (birth years of children, menopause status), 
use of oral contraceptives (OCs) and hormone replacement therapy (HRT), and history of all 
mammograms in the 5 years before diagnosis (including date, place and provider) were collected 
in the self-administered questionnaire. We sought to confirm dates of mammograms in 
BreastScreen Australia records from 1990 and in Medicare records from 1996 and used this 
information to construct a mammogram history for each woman. Based on the observed pattern 
of mammograms before surgical treatment of breast cancer, we defined the diagnosis 
mammogram as the earliest mammogram, in the 84 days before histopathological diagnosis of 
the breast cancer, that detected the cancer or contributed to its diagnosis. All preceding 
mammograms were classified as pre-diagnosis mammograms. Under a biennial screening 
policy, two screening mammograms should have been done in the 4.5 years before diagnosis of 
breast cancer. Thus two or more mammograms in this period were considered to indicate that a 
woman was having regular mammograms, fewer than this were considered to indicate no 
regular mammograms. Percent mammographic density was measured in a subset of 665 women 
who attended BreastScreen Australia and had a mammogram before the diagnosis mammogram. 
Mammograms were randomised into reading sets of approximately 100 and measured by a 
single reader (JS) using a computer-thresholding technique [10] and blinded to all identifying 
information. A 10% random sample of mammograms was repeated in each set and between 
every third set to test reliability of the measurement.  
The CATI began with the question “How was your breast cancer first discovered?” in 
response to which women identified one of two methods of detection: a breast change 
(symptom), including presence of a breast lump, was noticed by the woman, her partner, or a 
doctor (a symptom detected breast cancer), or the cancer was detected by screening 
mammography (a mammogram detected breast cancer).  
The CATI also asked for weight, height, history of breast changes before diagnosis, family 
history of breast cancer, personal history of other cancers, residence at diagnosis, education, 
employment, marital status, health insurance, use of health care, breast checks by self or a doctor 
in the 2 years before the events that led to diagnosis, and smoking and alcohol use. All women 
were considered to be postmenopausal if they had undergone natural menopause (menstruation 
cessation) or had ovaries removed. Natural and surgical menopause were combined for analysis. 
Age at menopause was imputed for women who reported a hysterectomy, based on predictor 
variables of age at natural menopause [11] in women in our study. HRT use was assigned as 
current for women who said they were taking HRT at the time of diagnosis and past if they had 
stopped. We used WHO categories for body mass index (BMI): <25 (underweight, normal), 25-
29 (overweight) and ≥ 30kg/m2 (obese) [12]. Pathology characteristics (cancer type, size, grade, 
estrogen receptor (ER) status, cancer in lymph nodes) were abstracted from pathology reports 
and are included in these analyses as possible indicators of the behavior of breast cancers in the 
pre-detection phase. Categories used for variables are given in the relevant results tables. 
Statistical analysis 
We examined the association of characteristics of the women and characteristics of the 
cancer with detection as a result of symptoms (symptom detection), relative to mammogram 
detection, and calculated odds ratios (ORs) and 95% confidence intervals (CIs) in logistic 
regression models adjusted for age at diagnosis in 5 year age groups and state of residence (New 
South Wales, Victoria, Queensland). Women who had regular mammograms before diagnosis 
and those who did not were analysed separately. Variables with p for heterogeneity <0.1 in 
single variable analyses in either group of women were selected as candidate variables for 
inclusion in multivariable analyses. Age, state of residence and menopausal status were included 
in all models regardless of p value. HRT use was analysed only in postmenopausal women.  
The final multivariable model in each group of women was also used to examine ORs 
relating BMI to detection method in additional analyses stratified by smoking and cancer 
characteristics: size, grade, and ER status. We also did analyses of the associations of BMI and 
age with detection method stratified by ER status. To assist in evaluating the presence of effect 
modification in each of these instances, a cross product term was added to the logistic regression 
model and a p value for interaction calculated using the Wald test to compare the model with 
main effects only with a model with main effects and the cross product term. SAS software 
version 9.1 was used for the statistical analyses. 
RESULTS 
The women included in these analyses were aged 40-69 years (1,459 women); 460 were 40-
49 (32%) and 999 were 50-69 years of age (68%). For a more detailed description of 
participants, see Kricker et al [9]. The initial study included 1,602 women with breast cancer 
(79% of 2,024 ascertained) who were 22–69 years of age and residents of NSW (38%), Victoria 
(34%), and Queensland (28%). By design, all women had breast cancers that were 1.1 cm or 
larger. 
Most breast cancers were symptom detected (65%, 946/1459), more commonly in women 
40-49 (86%) than 50-69 (55%) years of age, and most symptom detected cancers (61%, 574 of 
946) were in women who did not have regular mammograms. The frequency of symptom 
detected cancers was higher in women with no regular mammograms (82%) than regular 
mammograms (49%) (OR=3.04, 95% CI 2.33-3.98; p value <0.001, associated with no regular 
mammograms); thus lack of regular mammograms before diagnosis was the strongest risk factor 
for a symptom detected cancer. Given the dominance of this risk factor, our analyses examine 
the correlates of symptom detected breast cancers separately in women who had regular 
mammograms and women who had irregular or no mammograms before their diagnosis of 
breast cancer. 
We first analysed the correlates of symptom detected cancers in 748 women 40-69 years 
who had regular mammograms before diagnosis. Almost all of the symptom-detected breast 
cancers (92%) were diagnosed within two years of the last screening mammogram. Being 40-49 
years of age was the strongest correlate of symptom detected breast cancers in these women: the 
ORs fell with age from OR=2.51 at 40-49 to OR=0.71 at 65-69 years (Table 1). Postmenopausal 
women had a somewhat lower odds for symptom detection than premenopausal women 
(OR=0.69; p=0.21). The OR for symptom detected breast cancer was also increased with a low 
BMI (OR for <25 kg/m2=2.00), any history of breast changes in the years before diagnosis 
(OR=1.54), and with cancers that were larger (OR for 3+cm=7.88, relative to 1-1.9cm; 73% of 
the mammogram detected cancers were 1.1-1.9cm), high grade (OR=3.89), node positive (OR 
for 3+ nodes=4.38) and ER− (OR=2.45) (all p<0.001). In 619 postmenopausal women, the OR 
for symptom detection with current HRT use was 1.81 (p value 0.004; Table 1). Models for each 
variable in these analyses were adjusted for age and state. 
We constructed a multivariable model in women who had had regular mammograms before 
diagnosis to include all variables with p<0.1 in these women (see Table 1) and in women who 
had irregular or no mammograms before diagnosis(Table 3). The variables examined were age, 
BMI, whether a first cancer, regular breast examination by a doctor, reporting a breast change in 
the years before diagnosis, smoking, cancer size and grade, nodal status and ER status, and 
menopause status and state of residence as potential confounders. BMI <25kg/m2, any history of 
breast changes, higher grade, larger size, positive lymph nodes, and HRT use in postmenopausal 
women were each independently associated with symptom detected cancers (Table 1; p≤0.05 in 
each case). Age was inconsistently associated with symptom detection in this model (p=0.51) 
and the positive association with ER− status was substantially attenuated, mainly because of 
confounding with cancer grade. Postmenopausal women’s current use of HRT increased the 
odds of symptom detection for smaller cancers, OR for 1.1-1.9cm=3.77 (95% CI 2.02-7.03), but 
not larger cancers, OR for ≥2cm=0.52 (95% CI 0.24-1.11) (p for interaction=0.002).  
We fitted the same multivariable model in 665 women who were aged 50-69 years, the 
target age for women invited to attend BreastScreen Australia, and had regular mammograms 
before diagnosis. The ORs for all variables were very similar to those in all women.  
Mammographic density was available for 698 women 40-69 years of age. Increasing density 
increased the odds of symptom detection in all women when modeled with age, personal and 
cancer characteristics. Relative to the lowest quarter (Q1), the ORs were: Q2=1.4, 95% CI 0.89-
2.42, Q3=1.87, 95% CI 1.11-3.16, Q4=2.52 95% CI 1.47-4.32 (p=0.008). In the 498 women who 
had regular mammograms, low BMI, a history of any breast change (each OR ~2.0), current 
smoking, greater breast density, larger cancer size, higher grade (each OR 3.0 or greater) were 
independently associated with symptom detection (Table 2). In a similar model limited to 
postmenopausal women who had regular mammograms, current HRT use increased the OR for 
symptom detected cancers (OR=1.67, 95% CI 0.93-2.99; p value 0.22).  
We next analysed the correlates of symptom detected cancers in the 696 women who did not 
have regular mammograms before diagnosis; 68% of these women had one mammogram in the 
4.5 years before diagnosis and the others had none. In a multivariable model similar to that 
described above, fully adjusted ORs for a symptom detected breast cancer in women who had no 
regular mammograms were increased only for being 40-49 years of age (OR=2.96 at 40-44 and 
2.10 at 45-49 years), having a first cancer (OR=2.23), larger cancer size (OR=2.26 for 2.0-2.9 
and OR=2.22 for 3+ cm) and high cancer grade (OR=2.08) (Table 3; p≤0.05 in each case). There 
were too few women with mammographic density measurements (193) to include density in a 
fully adjusted model. However, there was only weak evidence that density was associated with 
symptom detected cancer in these women when adjusted only for age and state of residence: OR 
for Q2=1.11, 95% CI 0.44-2.79, Q3=1.91, 95% CI 0.75-4.83, Q4=1.85, 95% CI 0.76-4.52; 
ptrend=0.11.  
We also fitted the fully adjusted model separately in women aged 40-49 and 50-69 years 
who had irregular or no mammograms before diagnosis. In 321 women 50-69 years, only cancer 
size and estrogen receptor status were independently associated with symptom detected cancers: 
the OR was OR=3.42 (95% CI 1.38-8.45) for 3cm+ cancers (p value for model <0.001) and 
OR=2.50 (95% CI 1.11-5.66) for ER− cancers (p value for model=0.03). The OR for high grade 
fell to OR=1.54 (95% CI 0.65-3.62; p value for model=0.67) and the association with being a 
first cancer weakened (OR=1.75, p=0.31). To examine these same factors in women 40-49 
years, who had only 35 mammogram-detected cancers, we re-categorised most as dichotomous 
variables. The ORs were increased for high grade (OR=3.45, 95% CI 1.29-9.22; p=0.01) relative 
to low or intermediate grade cancers, and for being a first cancer (OR=4.20, 95% CI 1.20-14.67; 
p=0.02). The OR in women aged 40-44 was OR=1.96 (95% CI 0.88-4.34), relative to 45-59 
years, but the p value was 0.10. 
Other personal (SES, marital status, education, country of birth, cancer type), and health or 
behavioral characteristics examined (employment, urban or rural residence, parity, OC use, 
breast cancer in 1st degree relative, health insurance status, alcohol use) had ORs for a symptom 
detected cancer of between 0.62 and 1.36 and p values >0.1. Each variable was examined 
separately in each group of women, those who had regular mammograms and those who did not, 
in a model adjusted for age and state of residence (results not shown). 
Smoking appeared to modify the association of BMI with symptom detected cancers in all 
1,459 women 40-69 years. The fully adjusted OR for a symptom detected cancer with BMI 
<25kg/m2 relative to 25+kg/m2 was 5.86 (95% CI 1.68-20.48) in current smokers and OR=1.68 
(95% CI 1.27-2.22) in former or non-smokers (p for interaction=0.04). This observation was 
similar in women who did not have regular mammograms (p for interaction=0.07). There were 
only 45 current smokers in women who had regular mammograms, and so the OR for a 
symptom detected cancer with BMI <25kg/m2 in current smokers was estimated with adjustment 
for age and state only, OR=44.44 (95% CI 4.33-456.54). The fully adjusted OR for a symptom 
detected cancer with BMI <25kg/m2 in non- or former smokers was 2.48 (95% CI 1.73-3.57). 
The association of symptom detected breast cancers with BMI did not vary across categories of 
cancer size or grade or HRT use in postmenopausal women.  
The average cancer size in our study tended to be smaller in low BMI women, 1.99cm in 
those with regular mammograms before diagnosis and 2.25cm with irregular or no 
mammograms, than in those with higher BMI, 2.17cm with regular mammograms and 2.62cm 
with irregular or no mammograms (p <0.05 in each case). The proportions with high grade 
lesions, cancer in the nodes, and ER− cancers, however, did not vary by BMI.  
Although the association of estrogen receptor status with symptom detected cancers was 
weakened in the fully adjusted models due to confounding with cancer grade, we explored its 
relationship with BMI because of evidence elsewhere that estrogen receptor status modifies the 
association of BMI with breast cancer risk [13]. In women who had regular mammograms the 
OR was higher for symptom detected cancers with BMI <25 kg/m2 in ER− cancers (OR=6.60, 
95% CI 2.45-17.79) than in ER+ cancers (OR=2.00, 95% CI 1.33-3.01; p for interaction=0.01) 
(Table 4). In women who had irregular or no mammograms, it was also higher in ER− cancers 
(OR=4.18, 95% CI 1.12-15.61) than in ER+ cancers (OR=0.83, 95% CI 0.50-1.38) (p for 
interaction 0.11).  
DISCUSSION  
As would reasonably be expected, not having regular mammograms was the strongest 
predictor of a symptom detected breast cancer in women 40-69 years of age. In women who 
were diagnosed with breast cancer and had regular mammograms before diagnosis, the breast 
cancer was more likely to have been detected following symptoms than a screening 
mammogram when there was a low BMI, greater breast density, current HRT use, a history of 
breast changes, a >2cm or higher grade breast cancer and nodal metastases at diagnosis. 
However, HRT was not associated with symptom detection when breast density was included in 
the statistical model in a subset of women with density measurements. Only younger age, being 
a first cancer, and a >2cm breast cancer were independently associated with a symptom detected 
breast cancer in women who did not have regular mammograms. Smoking and estrogen receptor 
status appeared to modify the association of a low BMI with symptom detected breast cancers in 
both groups of women, the association being stronger in current smokers than former or non-
smokers and in women with ER− cancers than ER+ cancers.  
In women who had regular mammograms, almost all of the symptom-detected breast 
cancers were diagnosed within two years of the last screening mammogram, that is, they were 
interval cancers. This was probably due, in part at least, to the fact they were high grade and 
therefore faster growing cancers [14]. It is also contributed to by BreastScreen Australia’s 
comparatively low program sensitivity (71.7% for second or later screening rounds in 2000-2002 
[15]) and the possibility that the sensitivity of private screening mammography is less than in 
organised screening [16].  
The association of symptom detected breast cancers with low BMI that we observed in 
women who had regular mammograms is consistent with more ready mammographic detection 
of breast cancer in heavier women [17,18], probably because fatty breasts are more radiolucent 
[18-20]. Reduced mammographic sensitivity may be part of the explanation, although only small 
differences in mammographic sensitivity have been reported between BMI categories (85.7% for 
BMI <25kg/m2, 91.0% for BMI >25kg/m2[21]). Greater symptom detection of breast cancer in 
women with low BMI might also reflect easier palpability of breast lumps in lean women [22], 
which is consistent with the greater frequency of interval cancers in normal weight than 
overweight postmenopausal women [23-25] and as breast density increases [25]. 
Mammographic density was inversely correlated with BMI in our study, an association 
consistently reported by others [26-28], especially in women with breast cancer [29]. The 
smaller average size of symptom detected cancers in women with a low BMI may also indicate 
easier and earlier diagnosis of breast cancer in lean women, as Willett et al have suggested [30].  
Having low estrogen activity is more probable for a woman with low BMI than high BMI 
[31], and could be part of the reason that women with low BMI were more likely to have ER− 
cancers than ER+ cancers detected symptomatically. Rather than greater detectability of ER− 
cancers in thinner women though, this association probably reflects more rapid growth of ER+ 
cancers in overweight or obese women. As de Waard put it: “ER+ cancer cells thrive and 
multiply in fat women” and “find no stimulus for multiplication” in lean postmenopausal women 
[23]. The stronger association of low BMI with symptom detected ER– than ER + cancers may 
also be due to less effective mammogram detection of ER– breast cancers [32-34]. 
A low BMI was more strongly associated with symptom detection in current smokers 
(OR=5.02) than in non- or former smokers (OR=1.60). Current smokers have been reported to 
have less dense breasts than former or non-smokers (absolute mammographic density 
percentages around 3-7% lower) [35-37], although we did not observe this in our study. Current 
smokers have also been recently reported to have higher levels of sex hormone binding globulin 
(SHBG) and free estradiol than former or non-smokers, with the former greater in lean women 
and the latter in overweight women [38]. The combination of high SHBG levels due to smoking 
with the high levels already present in lean women [39] would be expected to further reduce 
estrogen activity in lean women. If anything this might be expected to reduce the likelihood of 
symptom detected breast cancer in lean women rather than increase it. Thus we cannot readily 
explain the apparently strong modification by smoking of the association of low BMI with 
symptom detected breast cancer. 
That current HRT users who had regular mammograms were more likely to have symptom 
detected cancers was consistent with HRT reducing both the sensitivity and specificity of 
mammography [21,40]. The increased likelihood that smaller breast cancers were symptom 
detected in current HRT users is consistent with reduced effectiveness of mammography in 
denser breast tissue. Current HRT use was much more common in low (46%) than high BMI 
postmenopausal women (32%; p <0.001), and could have further increased breast density in low 
BMI women.  
A history of a breast change, 73% of which were breast lumps, was more common in 
women 50-59 years (57%) than 40-49 (50%) or 60-69 (46%) (p=0.02) and in women who had 
regular mammograms (54%) than women who did not (49%) (p=0.07). These observations 
suggest that women having regular mammograms may be more breast aware than women who 
do not, that they know the normal look and feel of their breasts. Breast awareness is 
recommended by cancer organisations (see, eg, http://canceraustralia.nbocc.org.au/view-
document-details/cwwb-breast-cancer-won-t-wait; 
http://www.cancerscreening.nhs.uk/breastscreen/breastawareness.html), even when women are 
having regular mammograms. Breast awareness may increase the detection of benign breast 
changes and of symptoms of breast cancer, thus making symptom detected breast cancer more 
likely and explaining the link we observed between previous breast changes and symptom 
detection in women having regular mammograms. 
Mammographic density was another factor independently associated with symptom detected 
breast cancers in women who had regular mammograms in our study, consistent with greater 
density reducing mammographic sensitivity [25,41,42]. Increasing density is also associated 
with increasing cancer size [41] and inversely with grade in interval cancers (ie, detected 
symptomatically) [43,44]. There was, however, no such correlation between grade and density in 
symptom detected cancers in our study. The ORs for mammographic density in our study 
changed only minimally when adjusted for BMI, age, cancer size and grade (see Table 2) and all 
except age remained independently associated with symptom detected breast cancers. Density, 
BMI and cancer size and grade appear to influence symptom detection of breast cancer 
independently of one another.  
The higher frequency of symptom detected cancers in women in their forties in our study is 
likely to be a consequence of the primary targeting of screening in BreastScreen Australia to 
women 50-69 years of age. In 2002-2003, BreastScreen Australia detected 15% of all breast 
cancers in women 4049 years (675 of 4453), who are not in the target age range but may 
attend, and 44% of all breast cancers in women 50-69 (5227 of 11760) [4,45]. Interestingly, the 
relatively greater OR for symptom detection in women 40-49 years who had regular 
mammograms was limited to ER+ cancers (OR=2.86 in ER+ vs OR=1.73 in ER− cancers); this 
was also evident in women who had irregular or no mammograms (OR=4.62 in ER+ vs 
OR=0.52 in ER− cancers) (Table 3). These observations suggest that higher estrogen levels in 
younger women increase the probability of symptom detected breast cancers.  
Our finding that symptom detected breast cancers in women with regular mammograms 
were more commonly high grade is consistent with previous observations [8,32,46,47]. That low 
grade cancers were more often mammogram-detected, as we and others have found [8,32,46,47], 
is consistent with the presumed longer mean sojourn time for low grade cancers.  
The strengths of this study are its population base and the rigor with which we sought to 
document the antecedents of and pathway to diagnosis of breast cancer. Women told us whether 
a routine mammogram or noticing a breast change led to detection of their breast cancer: 10% of 
women declare breast symptoms at a screening visit [48]. We had comprehensive information on 
dates of mammograms and confirmed the dates for all but 6% of women. Women’s recall of the 
number and calendar period of mammograms in the past 2 years agreed well with breast 
screening records. In addition, we had data on personal characteristics, risk factors for breast 
cancer and breast symptoms to analyse as covariates; all were self-reported.  
Lack of regular screening mammograms was the strongest correlate of symptom detected 
breast cancers. Of several other potentially important correlates of these cancers, low BMI was 
arguably the strongest in women who had regular mammograms and its association with 
symptom detection did not appear to be explained by any of the other variables measured. 
Tailored approaches to increase cancer detection could be considered in women of low BMI and 
women who smoke, for whom the likelihood of symptom detection is increased. It has been 
suggested that the likelihood of symptom detection in women with regular mammograms might 
be reduced if women more likely to have poor screening outcomes, such as women with high 
breast density, were identified (see, for example Kavanagh et al [41] and Schousboe [49]). In 
addition, given our findings, a tailored approach to increasing cancer detection might be 
considered in women of low BMI and women who smoke. It is possible, for example, that 
women of low BMI would benefit from receiving expert breast examination in addition to 
mammography screening, particularly if they also smoke. The apparent lack of effectiveness of 
addition of mammography to clinical breast examination in one Canadian screening trial has 
been taken to suggest that clinical breast examination is a useful alternative screening modality 
[3]. 
No ready intervention is available to address greater estrogen activity in younger women if 
it contributes to their higher frequency of symptom detected breast cancers. Regular screening 
for women 40-49 years is increasingly recommended. The US Preventive Services Task Force, 
however, did not recommend universal screening of women 40-49 years on the basis that the 
reduction in breast cancer mortality by starting screening mammography at age 40 may be only 
about 15% [50] and that earlier screening involves important harms [51]. 
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Table 1. Associations of personal, health and cancer characteristics with symptom 
detection of breast cancer relative to mammogram detection in 748 women aged 40-69 
years who had regular mammograms  
   Odds ratios for symptom detected cancers




a (95% CI) ORb (95% CI) 
Characteristic n=382 n=366 p value p value 
Age     
40-44 6 13 2.51 (0.92-6.88) 1.81 (0.48-6.81) 
45-49 21 43 2.49 (1.37-4.50) 1.61 (0.68-3.81) 
50-54 68 76 1.28 (0.83-1.96) 0.84 (0.49-1.44) 
55-59 112 99 1.0 1.0 
60-64 96 84 0.99 (0.66-1.47) 1.15 (0.72-1.83) 
65-69 79 51 0.71 (0.46-1.11) 0.94 (0.56-1.58) 
   p=0.002 p=0.51 
BMI     
30+ kg/m2 116 78 1.0 1.0 
25-29 kg/m2 133 95 1.01 (0.68-1.50) 1.17 (0.74-1.86) 
<25 kg kg/m2 130 193 2.00 (1.39-2.90) 2.96 (1.90-4.61) 
   p trend<0.001 p <0.001 
Menopausal status      
premenopausal 45 81 1.0 1.0 
postmenopausal 337 285 0.69 (0.38-1.23) 0.60 (0.31-1.17) 
   p=0.21 p=0.13 
1st cancer of any kind     
no 43 33 1.0 1.0 
yes 336 333 1.15 (0.71-1.87) 1.23 (0.71-2.14) 
   p=0.57 p=0.46 
Regular breast exam by Dr     
yes 238 233 1.0 1.0 
no 144 133 1.03 (0.76-1.40) 1.01 (0.71-1.44) 
   p=0.83 p=0.95 
     
Breast change (any time)     
none 195 147 1.0 1.0 
any 187 219 1.54 (1.14-2.07) 1.73 (1.23-2.44) 
   p=0.005 p=0.002 
Smoking     
never 226 203 1.0 1.0 
former 138 136 1.04 (0.77-1.42) 1.14 (0.80-1.63) 
current 18 27 1.73 (0.91-3.26) 2.02 (0.98-4.16) 
   p=0.24 p=0.15 
Cancer characteristic     
Cancer size      
1.1-1.4cm 158 73 1.0 1.0 
1.5-1.9cm 133 89 1.52 (1.02-2.26) 1.52 (0.99-2.34) 
2.0-2.9cm 65 112 3.81 (2.50-5.81) 3.13 (1.96-5.01) 
   Odds ratios for symptom detected cancers




a (95% CI) ORb (95% CI) 
Characteristic n=382 n=366 p value p value 
3.0+cm 26 92 7.88 (4.66-13.33) 6.55 (3.58-11.96) 
   <0.001 <0.001 
Grade     
low 100 50 1.0 1.0 
moderate 183 139 1.49 (0.99-2.25) 0.95 (0.60-1.50) 
high 86 172 3.89 (2.52-6.00) 2.41 (1.41-4.10) 
not reported 13 5 0.69 (0.22-2.12) 0.58 (0.17-1.95) 
   p trend<0.001 p<0.001 
Lymph nodes positive     
none 226 158 1.0 1.0 
1-2 76 91 1.65 (1.13-2.39) 1.23 (0.81-1.88) 
3 or more 29 85 4.38 (2.72-7.05) 2.40 (1.39-4.16) 
not reported 51 32 0.95 (0.57-1.56) 1.05 (0.61-1.83) 
   p trend <0.001 p=0.02 
     
ER status     
positive 311 250 1.0 1.0 
negative 52 102 2.45 (1.68-3.58) 1.17 (0.72-1.90) 
not reported 19 14 0.82 (0.40-1.71) 0.77 (0.33-1.78) 
   p<0.001 p=0.65 
Postmenopausal women only    
HRT usec     
never 118 79 1.0 1.0 
former  93 66 1.11 (0.72-1.71) 0.96 (0.57-1.60) 
current 123 140 1.81 (1.24-2.66) 1.80 (1.15-2.83) 
   p=0.004 p=0.008 
Regular mammograms were defined as two at intervals of 2 years or three at intervals of 1 year in 
the 4.5 years before diagnosis. 
a Adjusted for age and state of residence; p for trend calculated on categories excluding ‘not 
reported’. 
b Adjusted for age, state of residence and all other variables in the Table except HRT 
c  Estimates calculated in 619 postmenopausal women (N= 334 mammogram detected, N=285 
symptom detected); fully adjusted model includes all other variables in the Table. 
 
 
Table 2. Associations of personal, health and cancer characteristics with symptom detection 
of breast cancer relative to mammogram detection in 497 women with breast density who had 
regular mammograms.  
   Odds ratios for symptom detected cancers




a (95% CI) ORb (95% CI) 
Characteristic n=257 n=240 p value p value 
Age     
40-44 3 5 1.52 (0.20-11.35) 1.16 (0.15-9.00) 
45-49 12 22 1.28 (0.40-4.03) 1.14 (0.36-3.65) 
50-54 45 48 0.68 (0.34-1.34) 0.67 (0.33-1.34) 
55-59 80 72 1.0 1.0 
60-64 63 56 1.11 (0.63-1.95) 1.33 (0.74-2.39) 
65-69 54 37 0.90 (0.48-1.68) 1.15 (0.60-2.19) 
   p=0.65 p=0.53 
BMI     
30+ kg/m2 75 54 1.0 1.0 
25-29 kg/m2 91 60 1.23 (0.69-2.18) 1.04 (0.57-1.87) 
<25 kg kg/m2 91 126 3.03 (1.75-5.26) 2.25 (1.27-4.00) 
   p<0.001 p=0.003 
Menopausal status     
Pre 28 45 1.0 1.0 
Post 229 195 0.55 (0.23-1.30) 0.57 (0.24-1.38) 
   p=0.17 p=0.21 
1st cancer of any kind     
no 30 16 1.0 1.0 
yes 227 224 1.68 (0.81-3.49) 1.58 (0.75-3.35) 
   p=0.17 p=0.23 
Regular breast exam by Dr    
 152 146 1.0 1.0 
yes 105 94 0.93 (0.61-1.42) 0.97 (0.62-1.50) 
no   p=0.72 p=0.88 
     
Breast change (any time)     
none 144 107 1.0 1.0 
any 113 133 2.05 (1.34-3.14) 1.92 (1.24-2.98) 
   p<0.001 p=0.004 
Smoking     
never 152 132 1.0 1.0 
former 94 87 1.19 (0.77-1.86) 1.24 (0.79-1.96) 
current 11 21 3.09 (1.27-7.50) 3.39 (1.35-8.51) 
   p=0.04 p=0.03 
Breast density     
Quartile 1 88 35 - 1.0 
Quartile 2 71 61 - 1.94 (1.05-3.59) 
Quartile 3 60 65 - 2.47 (1.30-4.68) 
   Odds ratios for symptom detected cancers




a (95% CI) ORb (95% CI) 
Characteristic n=257 n=240 p value p value 
Quartile 4 38 79 - 3.90 (1.97-7.71) 
    p=0.001 
Cancer characteristic     
Cancer size      
1.1-1.4cm 100 43 1.0 1.0 
1.5-1.9cm 87 61 1.63 (0.95-2.79) 1.59 (0.92-2.75) 
2.0-2.9cm 51 78 3.10 (1.73-5.54) 2.82 (1.55-5.11) 
3.0+cm 19 58 6.93 (3.30-14.55) 6.35 (2.97-13.57) 
   p<0.001 p<0.001 
     
Grade     
low 67 33 1.0 1.0 
moderate 116 88 1.00 (0.57-1.77) 1.01 (0.57-1.80) 
high 64 116 2.74 (1.42-5.28) 2.91 (1.49-5.70) 
not reported 10 3 0.41 (0.09-1.91) 0.43 (0.09-2.11) 
   p<0.001 p<0.001 
Lymph nodes positive     
none 155 108 1.0 1.0 
1-2 52 62 1.35 (0.81-2.27) 1.24 (0.73-2.11) 
3 or more 19 52 2.72 (1.35-5.47) 2.62 (1.28-5.35) 
not reported 31 18 1.10 (0.53-2.29) 1.06 (0.50-2.26) 
   p=0.04 p=0.07 
ER status     
positive 208 162 1.0 1.0 
negative 38 69 1.08 (0.59-1.97) 1.11 (0.60-2.06) 
not reported 11 9 1.13 (0.38-3.33) 1.26 (0.41-3.89) 
   p=0.95 p=0.88 
     
Regular mammograms were defined as two at intervals of 2 years or three at intervals of 1 year in 
the 4.5 years before diagnosis. 
a Adjusted for age and state of residence; p for trend calculated on categories excluding ‘not 
reported’. 
b Adjusted for age, state of residence and all other variables in the Table  
 
Table 3. Associations of personal, health and cancer characteristics with symptom detection 
of breast cancer relative to mammogram detection in 696 women aged 40-69 years who had 
no regular mammograms  
   Odds ratios for symptom detected cancers
   adjusted for age and state  fully adjusted  
 Mammogram detected 
Symptom 
detected OR
a (95% CI) ORb (95% CI) 
Characteristic n=126 n=570 p value p value 
Age     
40-44 14 164 3.37 (1.56-7.26) 2.96 (1.13-7.74) 
45-49 24 173 1.99 (1.00-3.98) 2.10 (0.89-4.98) 
50-54 41 109 0.73 (0.38-1.41) 0.76 (0.36-1.59) 
55-59 17 59 1.0 1.0 
60-64 17 38 0.67 (0.30-1.47) 0.69 (0.29-1.64) 
65-69 13 27 0.63 (0.27-1.49) 0.52 (0.21-1.31) 
   p<0.001 p=0.003 
BMI     
30+ kg/m2 27 124 1.0 1.0 
25-29 kg/m2 36 160 0.91 (0.51-1.60) 0.99 (0.54-1.81) 
<25 kg kg/m2 63 286 0.82 (0.49-1.39) 1.04 (0.59-1.81) 
   p=0.75 p=0.98 
Menopausal status      
premenopausal 48 333 1.0 1.0 
postmenopausal 78 237 0.94 (0.53-1.64) 0.81 (0.44-1.49) 
   p=0.81 p=0.50 
1st cancer of any kind     
No 13 30 1.0 1.0 
Yes 113 540 1.97 (0.96-4.04) 2.23 (1.03-4.84) 
   p=0.06 p=0.04 
Regular breast exam by Dr    
Yes 71 292 1.0 1.0 
No 55 278 1.49 (0.99-2.24) 1.43 (0.92-2.22) 
   p=0.06 p=0.11 
Breast change (any time)    
none 67 286 1.0 1.0 
any 59 284 1.11 (0.74-1.67) 1.15 (0.75-1.76) 
   p=0.61 p=0.52 
Smoking     
Never 62 294 1.0 1.0 
Former 49 188 0.68 (0.44-1.05) 0.73 (0.46-1.16) 
Current 15 88 1.26 (0.67-2.36) 1.20 (0.62-2.35) 
   p=0.10 p=0.25 
Cancer characteristic     
Cancer size      
1.1-1.4cm 36 98 1.0 1.0 
1.5-1.9cm 45 128 1.00 (0.58-1.70) 0.92 (0.52-1.64) 
2.0-2.9cm 27 196 2.67 (1.49-4.78) 2.26 (1.21-4.20) 
   Odds ratios for symptom detected cancers
   adjusted for age and state  fully adjusted  
 Mammogram detected 
Symptom 
detected OR
a (95% CI) ORb (95% CI) 
Characteristic n=126 n=570 p value p value 
3.0+cm 18 148 2.99 (1.57-5.69) 2.22 (1.08-4.55) 
   p<0.001 p=0.003 
Grade     
low 30 82 1.0 1.0 
moderate 64 235 1.36 (0.81-2.29) 1.31 (0.75-2.27) 
high 30 235 2.76 (1.54-4.96) 2.08 (1.08-4.02) 
not reported 2 18 3.26 (0.68-15.62) 4.16 (0.79-21.83) 
   p=0.003 p=0.08 
Lymph nodes positive     
none 73 275 1.0 1.0 
1-2 31 138 1.22 (0.75-1.98) 1.11 (0.66-1.87) 
3 or more 12 118 2.28 (1.17-4.44) 1.53 (0.73-3.17) 
not reported 10 39 1.32 (0.61-2.86) 1.58 (0.70-3.59) 
   p=0.11 p=0.52 
ER status     
positive 104 403 1.0 1.0 
negative 19 134 1.99 (1.16-3.43) 1.50 (0.81-2.78) 
not reported 3 33 2.90 (0.85-9.90) 2.51 (0.69-9.08) 
   p=0.01 p=0.19 
Postmenopausal women only    
HRT usec     
never 45 133 1.0 1.0 
former  9 36 1.53 (0.67-3.47) 1.93 (0.77-4.83) 
current 24 68 1.07 (0.59-1.93) 1.21 (0.61-2.39) 
   p=0.60 p=0.36 
Women in this table had 1 or no mammogram in the 4.5 years before diagnosis  
a Adjusted for age and state of residence; p-trend calculated on categories excluding ‘not reported’. 
b Adjusted for age, state of residence and all other variables in the Table except HRT. 
c Estimates calculated in 315 postmenopausal women (N= 78 mammogram detected, N=237 





Table 4  Associations of BMI and age, with symptom detection of breast cancer, relative to mammogram detection, stratified 
by estrogen receptor status.  
 regular mammograms  n=714a
 no regular mammograms 
n=661a
ER status factor Mammogram detected 
Symptom 
detected OR
b (95% CI)  Mammogram detected 
Symptom 
detected OR
b (95% CI) 
 BMI        
ER+  25+kg/m2 197 123 1.0  48 198 1.0 
 <25kg/m2 112 127 2.00 (1.33-3.01)  56 205 0.83 (0.50-1.38) 
         
ER−  25+kg/m2 38 43 1.0  13 68 1.0 
 <25kg/m2 13 59 6.60 (2.45-17.79)  6 66 4.18 (1.12-15.61) 
    p interaction 0.01    p interaction 0.11 
 Age        
ER+  50-69 291 207 1.0  75 154 1.0 
 40-49 18 43 2.75 (1.20-6.34)  29 249 3.95 (2.07-7.54) 
         
ER−  50-69 45 92 1.0  11 63 1.0 
 40-49 6 10 0.56 (0.09-3.58)  8 71 0.48 (0.10-2.38) 
    p interaction 0.02    p interaction 0.12 
Regular mammograms:  two at intervals of 2 years or three at intervals of 1 year in the 4.5 years before diagnosis.  
No regular mammograms: 1 or no mammogram in the 4.5 years before diagnosis  
a  numbers are: regular mammograms, ER+ 559, ER- 153; no regular mammograms, ER+ 507, ER- 153.  
b  Adjusted for all variables in the multivariate models of Tables 1 and 3.  
 
 
